The Journal of Thoracic and Cardiovascular Surgery
Volume 126, Issue 1 , Pages 11-15 , July 2003

Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma

Read at the Eighty-second Annual Meeting of The American Association for Thoracic Surgery, Washington, DC, May 5-8, 2002.

  • Raja M Flores, MD

      Affiliations

    • Thoracic Service, Department of Surgery, New York, New York, USAa
    • Corresponding Author InformationAddress for reprints: Raja M. Flores, MD, Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    • ,
  • Timothy Akhurst, MD

      Affiliations

    • Nuclear Medicine Service, Department of Radiology, New York, New York, USAb
    • ,
  • Mithat Gonen, PhD

      Affiliations

    • Biostatistics Service, Department of Epidemiology and Biostatistics,c Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Steven M Larson, MD

      Affiliations

    • Nuclear Medicine Service, Department of Radiology, New York, New York, USAb
    • ,
  • Valerie W Rusch, MD

      Affiliations

    • Thoracic Service, Department of Surgery, New York, New York, USAa

Received 17 July 2002 ,Revised 25 November 2002 ,Accepted 19 December 2002.

References 

  1. Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma (comparison of CT and MR imaging). Am J Radiol. 1999;172:1039–1047
  2. Patz EF, Shaffer K, Piwnica-Worms DR, Jochelson M, Sarin M, Sugarbaker DJ, et al.  Malignant pleural mesothelioma (value of CT and MR imaging in predicting resectability). Am J Roentgenol. 1992;159:961–966
  3. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1996;111:815–826
  4. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma (results of 183 patients). J Thorac Cardiovasc Surg. 1999;117:54–65
  5. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al.  A phase II trial of surgical resection and adjuvant high dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–795
  6. Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R, et al.  Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000;120:128–133
  7. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114:713–722
  8. The International Mesothelioma Interest Group . A proposed new international TNM staging system for malignant pleural mesothelioma. Chest. 1995;108:1122–1128
  9. American Joint Committee on Cancer. AJCC cancer staging handbook. 6th ed. New York, Berlin: Springer
  10. Union Internationale Contre le Cancer . TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002;

PII: S0022-5223(03)00207-1

doi: 10.1016/S0022-5223(03)00207-1

The Journal of Thoracic and Cardiovascular Surgery
Volume 126, Issue 1 , Pages 11-15 , July 2003

Article Tools

* Image Usage & Resolution